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Abstract: The co-expression of androgen (AR) and estrogen (ER) receptors, in terms of higher AR/ER
ratio, has been recently associated with poor outcome in ER-positive (ER+) breast cancer (BC) patients.
The aim of this study was to analyze if the biological aggressiveness, underlined in ER+ BC tumors
with higher AR/ER ratio, could be due to higher expression of genes related to cell proliferation. On a
cohort of 47 ER+ BC patients, the AR/ER ratio was assessed by immunohistochemistry and by mRNA
analysis. The expression level of five gene proliferation markers was defined through TaqMan®-qPCR
assays. Results were validated using 979 BC cases obtained from gene expression public databases.
ER+ BC tumors with ratios of AR/ER ≥ 2 have higher expression levels of cellular proliferation genes
than tumors with ratios of AR/ER < 2, in both the 47 ER+ BC patients (P < 0.001) and in the validation
cohort (P = 0.005). Moreover, BC cases with ratios of AR/ER ≥ 2 of the validation cohort were mainly
assigned to luminal B and HER2-enriched molecular subtypes, typically characterized by higher
proliferation and poorer prognosis. These data suggest that joint routine evaluation of AR and ER
expression may identify a unique subset of tumors, which show higher levels of cellular proliferation
and therefore a more aggressive behavior.
Keywords: breast cancer; androgen receptor; estrogen receptor; crosstalk of nuclear receptors;
proliferation genes
1. Introduction
The cytoplasmic ligand-dependent transcription factor androgen receptor (AR) has gained increasing
attention as an important marker of breast cancer (BC) biology [1]. Nevertheless, its significance is
still unclear, since AR positivity has been associated with different clinical outcomes in BC patients,
according to their estrogen receptors (ER) status [2–5]. Besides, regarding AR positivity in BC subtypes,
immunohistochemistry (IHC)-surrogate subtype classification indicates that ER-positive/HER2-negative
(ER+/HER2-) cancers express AR more frequently (91%) than ER+/HER2-positive (HER2+) (68%),
ER-negative (ER-)/HER2+ (59%) and triple negative BC (TNBC) (32%); however assignment of intrinsic
molecular subtypes by gene expression analysis, reveals that AR levels are similar in luminal A, B and
HER2-enriched, but lowers in Basal-like subtypes [6,7]. Of note BC subtypes have widely shown to
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possess significant prognostic differences. These controversial results are in line with in vitro studies
displaying that AR may induce divergent proliferative responses in ER-positive (ER+) [8,9] and in
ER-negative (ER-) BC cell lines [10]. AR and ER expression may co-localize in both, normal and tumor
tissues, providing evidence for a possible crosstalk between signaling pathways of these hormone
receptors [9]. Recently, we and others have demonstrated that the AR and ER expression ratio
(AR/ER) could be associated with outcome in ER+ BC patients [11,12]. In fact, high AR and low ER
protein expression levels (AR/ER ratio ≥ 2) are significantly associated with aggressive clinical features,
tamoxifen resistance, as well as poor disease-free and overall survival [11]. Furthermore, from a
molecular point of view, ER+ tumors with higher AR protein levels, do not always result as a luminal
subtype using PAM50 gene expression classifier [12].
It has been demonstrated that AR has the ability to regulate cell cycle progression of breast tumors,
through activation of cell signal transduction pathways (e.g., PI3K/mTOR and MAPK) or even, by direct
binding of AR to gene promoters involved in cell proliferation [13,14]. Cell proliferation represents
one of the most important biological features contributing to cancer aggressiveness and recurrent
disease [15,16], thus the assessment of several gene markers, have been shown to provide higher
prognostic information in BC patients [17,18]. Among them, AURKA (kinase involved in microtubule
formation during chromosome segregation), CCNB1 (its product forms the maturation-promoting
factor—MPF) and UBE2C (required for the destruction of mitotic cyclins), encode proteins implicated
in the control of mitosis. Other gene markers are BIRC5, which encodes negative regulatory proteins
that prevent apoptotic cell death and MKI67, that encodes a nuclear protein usually increased in
proliferating cells. These genes, activated by different signaling pathways, play roles directly related
with cell cycle control and their expression is increased in BC cells [19]. Accordingly, different multigene
prognostic assays currently use AURKA, BIRC5, CCNB1, MKI67 and UBE2C as markers representing a
proliferation gene expression signature [20,21].
Considering these data, the aim of the present study was to analyze the relationship between
AR/ER ratio and proliferation markers (AURKA, BIRC5, CCNB1, MKI67 and UBE2C) in BC cases
grouped according to their AR/ER ratio levels (<2 vs. ≥2). Validation of this relationship was performed
using datasets of BC gene expression profiling retrieved from public databases.
2. Materials and Methods
2.1. Study Design and Population
We selected 47 ER+ primary invasive BC cases with matched fresh-frozen tissue, who underwent
surgery (between 2014 and 2017) at the Breast Unit of the Città della Salute e della Scienza University
Hospital of Torino, Turin—Italy. Specimens were under-vacuum seal inside the surgical theater
immediately after surgery, and kept at 4 ◦C until transfer to the pathology laboratory [22]. Once in
the pathology lab, from each specimen, at least one sample was taken, embedded in OCTTM
(Tissue-Tek®-Sakura, Torrance, CA, USA) compound, snap frozen in isopentane and stored at −80 ◦C.
Diagnostic samples were routinely processed to paraffin embedding with an automatic processor
(Leica ASP 300, Leica Microsystems, Wetzlar, Germany). For all cases the following clinico-pathological
data were collected: age, type of surgery (conservative surgery vs radical mastectomy), tumor size
(<20 mm vs. ≥20 mm), histological type, tumor grade, nodal involvement, vascular invasion, ER,
progesterone receptor (PgR), Ki67 and human epidermal growth factor receptor 2 (HER2) status.
In addition, nine ER- BC cases were studied to establish further comparison between them and ER+
tumors. Nine fresh-frozen samples, from non-neoplastic breast tissues, were used as controls. All BC
cases were classified following Saint Gallen Consensus meeting (St. Gallen) and American Society of
Clinical Oncology/College of American Pathologists Guideline (ASCO/CAP) recommendations [23,24].
Ethical approval for this study was obtained from the Comittee for human Biospecimen Utilization
(Department of Medical Sciences—ChBU). The same ethic institutional review board approved that
written consent from the patients was not needed, given the retrospective approach of the project and
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that the study did not interfere with diagnosis or treatment decisions. All the cases were anonymously
recorded and data were accessed anonymously.
2.2. Immunohistochemistry (IHC)
Histological review was performed for all cases. The most representative formalin-fixed
paraffin-embedded tissue block (FFPE) of each case was selected and new slides were obtained
for the assessment by IHC of all prognostic markers and AR. IHC was performed using an automated
slide processing platform (Ventana BenchMark AutoStainer, Ventana Medical Systems Inc., Tucson,
AZ, USA) with the following primary antibodies: prediluted anti-ERα rabbit monoclonal antibody
(SP1, Ventana Medical Systems Inc., Tucson, AZ, USA); prediluted anti-PgR rabbit monoclonal
antibody (1E2, Ventana Medical Systems Inc., Tucson, AZ, USA); anti-AR mouse monoclonal
antibody (AR441, diluted 1:50, Dako, Glostrup, Denmark); anti-Ki67 mouse monoclonal antibody
(MIB1, diluted 1:50, Dako, Glostrup, Denmark). Measurement of HER2 expression was performed by
anti-HER2 polyclonal antibody (A0485, diluted 1:800, Dako, Glostrup, Denmark). Fluorescence in situ
hybridization (FISH) for assessing HER2 gene amplification was performed on IHC equivocal cases
(score 2+) [25]. Positive and negative controls (omission of the primary antibody and IgG-matched
serum) were included for each immunohistochemical run.
The cut-off value for ER and PgR-positivity was set at ≥1%, as suggested by St. Gallen and
ASCO Guideline Recommendations [23,24] and the same cut-off was also adopted for AR positivity [3].
HER2 status was classified as negative (score 0, 1+ and 2+ by IHC but not amplified by FISH) or positive
(when scored 3+ by IHC or HER2 amplified by FISH) according to guidelines [23,26]. The percentage
of Ki67 positive cells was recorded and the cut-off for dichotomizing tumors with low and high
proliferative fraction was established at 20% [23,27].
2.3. RNA Extraction
From OCTTM (Tissue-Tek®-Sakura, Torrance, CA, USA) frozen blocks, 10 cryosections (20 µm
thick each section) were cut to extract RNA. The suitability of the material was evaluated on one frozen
section stained with hematoxylin and eosin, and extraction was performed from tumor samples with a
percentage of neoplastic cells higher than 80%. The 10 cryosections were collected in 1 mL of TRIzol®
(Life Technologies, Carlsbad CA, USA) in a 1.5 mL sterile Eppendorf tube, and processed according
to the manufacturer’s instructions. RNA pellets were resuspended in DEPC-treated water, and the
RNA concentrations were measured with a spectrophotometer (NanoDrop 1000, Thermo Scientific,
Wilmington, DE, USA). The RNA samples were stored at −80 ◦C until further analysis.
2.4. Reverse-Transcription PCR (RT-PCR)
One µg (1 µg) of total RNA from each sample was treated with DNase I (1 U/µL; Roche Diagnostics,
Mannheim, Germany). To obtain complementary DNA (cDNA), we used the high-capacity reverse
transcription kit (Applied Biosystems, Foster City, CA, USA) in a reaction mixture with the following
components: 1× reaction buffer, 4 mM dNTPs, 1× random hexamers, 0.5 U/µL RNAse inhibitor,
1.25 U/µL MultiScribe Reverse Transcriptase and DEPC-Treated water. The reaction mixture was
incubated at 25 ◦C for 10 min, at 37 ◦C for 2 h and finally at 85 ◦C for 5 min. RNA samples without reverse
transcriptase were reverse transcribed and used as negative controls for DNA contamination in PCR
analysis. RNA integrity and quality of cDNA synthesis were assessed by conventional PCR of control
housekeeping gene G6PDH. cDNA samples were amplified using the touchdown-PCR conditions first
reported by Korbie and Mattick [28]. Experiments were performed in a 25 µL reaction volume using
the following components: PCR reaction buffer (1× final), MgCl2 (1.5 mM final), dNTPs mix (200 µM
final), primers (each 0.5 µM final), MyTaq DNA polymerase (1.25 U final, Bioline Reagents Limited,
London, UK) and distilled water (dH2O). Primers, designed using the Oligo explorer 1.5 Software,
amplified a target of 215 bp (primer sequences: Fw. 5′-GAGGCCGTGTACACCAAGAT-3′ Rev.
5′-AGCAGTGGGGTGAAAATACG-3′). The reactions were performed on a PTC-100 Peltier Thermal
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Cycler (MJ Research, Inc., MA, USA) and PCR products were separated by electrophoresis on a 2%
agarose gel-stained with GelRed® (Biotium, Inc., Fremont, CA, USA).
2.5. qPCR Assays
cDNA samples were used to assess the expression of AR, ESR1, five cell proliferation gene
markers (AURKA, BIRC5, CCNB1, MKI67 and UBE2C) and two control housekeeping genes (ACTB and
GAPDH) through TaqMan®-qPCR assays. Assays consist of a pair of unlabeled PCR primers and a
TaqMan probe with a FAM dye label on the 5′ end and minor groove binder (MGB) and nonfluorescent
quencher (NFQ) on the 3′ end. TaqMan Gene Expression assays were purchased from Applied
Biosystems (Foster City, CA, USA). The assays include: AR (Assay ID: Hs00171172_m1); ESR1 (Assay
ID: Hs00174860_m1); AURKA (Assay ID: Hs01582072_m1); BIRC5 (Assay ID: Hs04194392_s1); CCNB1
(Assay ID: Hs01030099_m1); MKI67 (Assay ID: Hs01032442_m1); UBE2C (Assay ID: Hs00964100_g1);
ACTB (Assay ID: Hs02786624_g1); GAPDH (Assay ID: Hs02786624_g1). The cDNA was characterized
using the StepOne Real-Time PCR System (Applied Biosystems. Foster City, CA, USA).
Gene expression differences, as well as, AR/ER-qPCR ratio were calculated based on 2-∆∆Ct method.
Gene expression was classified as significantly different when the fold-change (FC) expression was at
least ±2 and P values lower than 0.05. A gene expression pooled proliferation score (cell proliferation
signature—CPS) was calculated, taking the average 2-∆∆Ct across the five cell proliferation gene markers
for a particular sample. qPCR experiments were carried out in three biological replicates, and from
each biological replicate, at least two technical replicates were also performed.
2.6. Validation Cohort
To validate the relationship between AR/ER ratio with cellular proliferation, BC gene expression
data were downloaded from NCI Genomic Data Commons (GDC) and are openly available at
https://gdc.cancer.gov. A total of 1093 primary BC samples were retrieved. Cases with missing
ER/PgR information, neoadjuvant therapy and male BCs were excluded, as well as, those classified
by PAM50 classifier as normal-like tumors [29]. Thus, 979 cases were finally selected for validation
analysis (Table S1). The gene expression data were provided with level 3 RSEM counts after upper
quartile normalization, to maintain the standardization of different platforms or housekeeping genes.
AR/ER ratio was calculated by dividing AR gene expression counts by ESR1 gene expression counts,
so ER+ BC samples were classified in two groups (cases with AR/ER ratio < 2 and cases with AR/ER
ratio ≥ 2).
From all retrieved samples gene expression levels of individual and pooled genes related with
cell proliferation (AURKA, BIRC5, CCNB1, MKI67 and UBE2C) were assessed to establish potential
associations with AR/ER ratio groups. For each gene, z-normalized expression value was retrieved,
and CPS was calculated as an average of the five genes. Using the same strategy, the genes AURKb,
BUB1B, BUB1, CDK1 and CHEK1 were independently evaluated as an additional BC cell proliferation
signature [30]. BC molecular subtypes were defined on the basis of the PAM50 classifier, a 50-gene
subtype predictor developed using microarray and quantitative reverse transcriptase polymerase chain
reaction data that incorporates the gene expression–based “intrinsic” subtypes luminal A, luminal B,
HER2-enriched, and basal-like [20]. The molecular subtype assignment was performed using the
R/Bioconductor package TCGABiolinks v. 2.7.1 [31].
2.7. AR-Ness Signature on Validation Cohort
To explore AR activity in the AR/ER ratio groups, we evaluate an AR signature recently reported
by Daemen and Manning [32] on the validation cohort. Briefly, expression of 14 and 31 genes related
to active or inactive/suppressed AR signaling, respectively, was assessed. Expression of each gene was
z-normalized and a score (AR-ness score) was defined as the average z-scored expression of 14 positive
signature genes, minus the average z-scored expression of 31 negative signature genes.
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2.8. Statistical Analyses
Pearson’s Chi square test and Fisher’s exact test were preliminary performed to compare clinical
categorical variables and to evaluate potential differences in the variable distribution among groups.
Student’s t-test was performed to determine significant differences in FC values between groups.
Test for median and means (Analysis of Variance-ANOVA) were performed. For more than two groups
Tukey HSD post-hoc test was performed. P-values < 0.05 (*), <0.01 (**), <0.001 (***) and <0.0001 (****)
were considered as statistically significant. All tables and graphs show the mean values of at least
three independent experiments. For GDC data, ANOVA, Kruskal Wallis H and Mann–Whitney U tests
were also used to assess the differences in gene expression between AR/ER < 2 and AR/ER ≥ 2 groups.
Statistical analyses were performed using SPSS v.21.0 (IBM Corporation) and Prism7 v.7.0a. (GraphPad)
statistical software, as well as, R: Language and Environment for Statistical Computing.
3. Results
3.1. Patients and Tumor Characteristics
Clinical and pathological features of 47 ER+, as well as, nine ER- primary invasive BCs are shown
in Table 1. Median age of ER+ patients at diagnosis was 62 years. Most of these tumors (76.6%) were
non-special type (IDC-NST), followed by mixed type (10.6%) and invasive lobular carcinomas (ILC)
(4.3%). Almost half of the ER+ cases (48.9%) were of grade 3, 63.8% were higher than 2 cm in size,
46.8% had not lymph node involvement at diagnosis and vascular invasion was observed in 85.1%
of the primary tumors. Following St. Gallen and ASCO/CAP Guideline recommendations [23,26],
positive IHC expression of PgR was observed in 63.8% of the ER+ cases; 23.4% were HER2+, 70.2% had
high expression levels of Ki67 (≥20%) and most of these cases were classified as luminal B-Like tumors
(74.5%). IHC expression of AR was observed in 41 cases (87.2%). On the other hand, ER- cases
preferentially had greater tumor size and histological grade, higher levels of Ki67, all of them were
negative for PgR expression and classified as non-luminal-like tumors according to the IHC-surrogate
subtype classification.
3.2. Assessment of AR/ER Ratio
ER+ cases (47 tumors) were used to assess the AR/ER ratio through IHC and qPCR analysis.
For the IHC AR/ER ratio, obtained using the percentage of nuclear staining of each receptor, range was
0 – (Carlsbad, CA, USA) in a 1.5 mL. 50 (mean 4,38). In order to assess the mRNA transcript ratios of AR
and ER (qPCR), we calculated 2−∆∆Ct differentials of AR and ER expression for each sample utilizing
the within-sample reference genes (average Ct) for normalization purposes. The qPCR AR/ER ratio
range was −535.6–61 (mean −24,33). Following previous reports, cases were grouped by the AR/ER
ratio cut-off (<2 vs. ≥2) which better differentiate patients by prognosis [11,12]. Ten cases (10/47, 21.3%)
showed higher AR/ER ratio (AR/ER ≥ 2) by both, IHC and qPCR methods, which further indicates a
significant positive correlation between protein and mRNA expression levels (P < 0.0001—Figure S1).
The clinico-pathological characteristics of ER+ BC cases are associated with AR/ER ratio cut-off (IHC
and qPCR methods) in Table 2. In the descriptive analysis, patients with a higher AR/ER ratio
were associated with the overexpression/amplification of the HER2 gene (HER2+; P = 0.01) and
also with the IHC-Surrogate subtype (P = 0.004), following St. Gallen and ASCO/CAP guideline
recommendations [23,24].
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Table 1. Clinical and histopathological characteristics of breast cancer (BC) patients studied.
Prognostic marker classification and IHC-surrogate subtype definition were established following St.
Gallen and ASCO/CAP guideline recommendations.
Characteristics ER + n (%) ER − n (%) P Value (Fisher Test)
Total number of patients 47 9 -
Median age (Interval) 62 (35–82) 60 (43–78) 0.591 *
Tumor Size
(missing 1 case)
<20 mm 17 (36.2) -
0.028
≥20 mm 30 (63.8) 9 (100)
Metastatic Lymph
nodes
pN0 22 (46.8) 7 (77.8)
0.230pN1–3 14 (29.8) 1 (11.1)
pN > 3 11 (23.4) 1 (11.1)
Grading
1 4 (8.5) -
0.0852 20 (42.6) 1 (11.1)
3 23 (48.9) 8 (88.9)
Histotype
IDC-NST 36 (76.6) 5 (55.6)
0.245
ILC 2 (4.3) -
Mixed type 5 (10.6) -
others 4 (8.5) 4 (44.4)
Vascular invasion
No 7 (14.9) 3 (33.3)
0.192
Yes 40 (85.1) 6 (66.7)
PgR
0 17 (36.2) 9 (100)
<0.0001
≥1 30 (63.8) -
Ki67
<20% 14 (29.8) 1 (11.1)
0.235
≥20% 33 (70.2) 8 (88.9)
HER2
Negative 36 (76.6) 6 (66.7)
0.399
Positive 11 (23.4) 3 (33.3)
AR
0 6 (12.8) 3 (33.3)
0.148
≥1% 41 (87.2) 6 (66.7)
IHC – Surrogate
Subtype
Luminal A-Like 12 (25.5) -
<0.0001
Luminal B-Like
(HER2-) 24 (51.1) -
Luminal B-Like
(HER2+) 11 (23.4) -
HER2+/ER- - 3 (33.3)
TNBC - 6 (66.7)
DC-NST (invasive ductal carcinom—non special type), ILC (invasive lobular carcinoma). * Student’s t-test.
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Table 2. Association of AR/ER ratio with clinico-pathological characteristics of ER+ cases.
Classification by AR/ER ratio of ER+ cases was concordant using both IHC and qPCR methods.
AR: androgen receptor; ER: estrogen receptor.





Total number of patients 37 (78.7) 10(21.3) -
Median Age (Interval) 62 (35–79) 65 (47–82) 0.309 *
Grading
1 3 (8.1) 1 (10)
0.2152 18 (48.6) 2 (20)
3 43 (16.1) 7 (70)
Tumor size
<20 mm 12 (33.3) 4 (40)
0.485
≥20 mm 24 (66.7) 6 (60)
Metastatic Lymph
nodes
0 20 (54.1) 2 (20)
0.1081–3 9 (24.3) 5 (50)
>3 8 (21.6) 3 (30)
Vascular invasion
No 4 (10.8) 3 (30)
0.155
Yes 33 (89.2) 7 (70)
PgR
<20% 26 (70.3) 4 (40)
0.136
≥20% 11 (29.7) 6 (60)
Ki-67
<20% 12 (32.4) 2 (20)
0.366
≥20% 25 (67.6) 8 (80)
HER2
Status
Negative 32 (86.5) 4 (40)
0.01
Positive 5 (13.5) 6 (60)
ER% Mean (interval) 78 (2–99) 21 (2–50) <0.001 *
AR% Mean (interval) 70 (0–99) 83 (50–100) 0.319 *
IHC – Surrogate
Subtype
Luminal A 12 (32.4) 0 (0)
0.004
Luminal B-Like
(HER2-) 20 (54.1) 4 (40)
Luminal B-Like
(HER2+) 5 (13.5) 6 (60)
* Student’s t-test.
3.3. Association of AR/ER Ratio with Genes Involved in BC Proliferation
AURKA, BIRC5, CCNB1, MKI67 and UBE2C are well characterized genes involved in proliferation
of BC cells [33]. The gene expression pooled proliferation score (CPS) from all these markers, showed that
ER+ BC patients with AR/ER ratio ≥ 2 (defined by both IHC and qPCR methods) have significantly
higher levels of proliferation (P < 0.001) compared to cases with AR/ER ratio < 2, even when only
ER+/HER2- cases were taken into account (P < 0.05). Furthermore, the score in cases with AR/ER
ratio ≥ 2 was similar to that observed in ER- BC patients (P > 0.05) (Figure 1A,B), usually characterized
for higher levels of proliferation [34]. These differences were not observed when tumors were grouped
only by ER% positivity levels, defined by IHC (Figure 1C). In contrast to proliferation gene signature
by qPCR, Ki67 tested by IHC was not differentially expressed depending on AR/ER ratio and ER
levels (Table 2 and Figure S2). To further address this divergent result, correlation analyses between
qPCR-MKI67 levels and Ki67-IHC score were carry out. In analyzed cases as a whole, a significant
positive correlation could be observed (P < 0.0001), however when analyses were performed according
to AR/ER ratio groups, the correlation decreased in cases with ratio < 2 (P = 0.012) and it was lost in
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the AR/ER ≥ 2 group (P = 0.730) (Figure S3). The same result was observed when correlation analyses
were separately performed between CPS score and Ki67-IHC score (Figure S4).
Figure 1. Gene expression cell proliferation signature (CPS) of BC cases grouped by AR/ER ratio,
defined by IHC and qPCR methods. Significantly higher levels of CPS were observed in BC cases with
ratio AR/ER greater than 2, in both, ER+ cases independently of HER2 status (A) and also in ER+/HER2-
cases (B). However, differences were not identified when tumors were divided by ER% positivity levels
(C). ER-: estrogen receptor negative <1%. IHC: immunohistochemistry. Tukey‘s multiple comparison
test - **** P < 0.001; * P < 0.05; ns: Not significant.
3.4. Association of AR/ER Ratio with Cellular Proliferation in Validation Cohort
A pooled gene expression analysis (CPS) of publicly available data sets was also performed
on 979 BC patients with available gene expression and complete clinical data. Clinico-pathological
characteristics of these patients according to the datasets are reported in Table S1. AR/ER ratio analysis
was performed on 742 ER+ cases. AR/ER ratio was calculated according to the AR and ER mRNA
gene expression; 4.4% of these cases (43/742 tumors) showed ratio values greater than two (AR/ER ≥2).
Pooled analysis of AURKA, BIRC5, CCNB1, MKI67 and UBE2C genes demonstrated that in this group,
proliferation levels were significantly higher (P = 0.005) compared with cases with ratio values lower
than two (AR/ER < 2) (Figure 2A). Similar results were observed from the analysis, independently
performed, using the additional BC cell proliferation signature (AURKb, BUB1B, BUB1, CDK1 and
CHEK1 genes—Figure 2B) (P = 0.01).
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Figure 2. Gene expression cell proliferation signatures (CPSs) of BC cases from GDC, grouped by
AR/ER ratio. (A) Significantly higher levels of CPS were observed in BC cases with ratio AR/ER greater
than 2, using AURKA, BIRC5, CCNB1, MKI67 and UBE2C as gene proliferation markers. (B) The same
result was observed when AURKb, BUB1B, BUB1, CDK1 and CHEK1 were used, in an independently
way, as additional genes to evaluated CPS. A.** P = 0.005211; **** P = 1.17 × 10−44; B.* P = 0.028;
**** P = 3.54 × 10−54; ER-: estrogen receptor negative cases; Kruskal–Wallis H test - *, **, ****.
In order to better stratify ER+ cases of the publicly available gene expression data sets, BC molecular
subtypes were defined using the PAM50 classifier and grouped in accordance with AR/ER ratio cut-off
(<2 vs. ≥2). Molecular subtype distribution was significantly different (P < 0.00001) between the
AR/ER ratio ≥ 2 BCs, preferentially assigned to luminal B (48.8%) and HER-2 enriched (25.6%) subtypes,
and the AR/ER ratio < 2 BCs mainly classified as luminal A (70.8%) (Figure 3).
Figure 3. Molecular subtype distribution of BC cases from GDC, grouped by AR/ER ratio. Cases with
ratio AR/ER ≥ 2 were distributed significantly different respect other groups and are mainly represented
by luminal B and HER2-enriched tumors. AR/ER ≥ 2 vs. AR/ER < 2: P < 0.00001*. ER− vs.
Other groups: P < 0.00001*. Numbers linked to colours in each bar correspond to total number of cases
and its percentage, N (%). ER−: estrogen receptor negative cases. * Chi-Square test (X2).
3.5. AR-Ness Signature Evaluation in Validation Cohort
In order to establish possible AR-driven BC tumors, we applied the AR-ness signature to cases
subdivided according to AR/ER ratio. As shown in Figure 4, cases with AR/ER ratio≥ 2 had a significant
higher score (score: 0.476) compared with cases with AR/ER ratio < 2 (score: 0.115). This means that in
cases with AR/ER ratio ≥ 2, AR-induced genes were on average expressed (active AR signaling) at high
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level than genes reflecting of inactive AR signaling. On the other side, and in agreement with Daemen
and Manning study [32], ER- cases had very low AR-ness score, generally indicating inactive/negative
AR-driven tumors.
Figure 4. AR-ness signature in BC cases from GDC, grouped by AR/ER ratio. Higher AR-ness score in
AR/ER ≥ 2 group indicates a more active AR signaling respect to cases in other groups. ER-: estrogen
receptor negative cases. Kruskal–Wallis H test - ** P = 0.004, **** P = 8.65 × 10−28.
4. Discussion
In this study, we have shown that BC cases with AR/ER ratio ≥ 2 (assessed by IHC and qPCR)
are characterized by an increased proliferation status defined by a pooled gene expression analysis
of AURKA, BIRC5, CCNB1, MKI67 and UBE2C proliferation markers. In addition, these carcinomas
preferentially pertain to Luminal B and HER2-enriched molecular subtypes, suggesting their more
aggressive behavior in comparison with the majority of ER+ BC cases.
The role of AR in BC is not totally clear. However, several reports indicate that AR is involved in
the regulation of cell proliferation. In particular, high AR expression levels can drive tumor proliferation
of ER- BC cell lines [35,36], whereas in ER+ BC cell lines AR expression has been usually associated
with decreased cell proliferation [8,9,37–39]. This dual role of AR, seems to be mainly explained by the
ability of AR to recognize not only androgen response elements (ARE), but also, estrogen response
elements (ERE) [9]. Consequently, AR compete with ER to regulate transcription of its target genes,
as in classic luminal tumors [1,40]. Interestingly, experiments in ER- BC cell lines, where AR was
specifically silenced or inhibited, showed a reduction in mRNA levels of those classic ER target genes,
accompanied with decreased cell proliferation [41].
On the whole, the above evidence allows hypothesizing that AR could promote expression of ER
target genes related with proliferation, by replacing ER when its levels are low or absent. The data
obtained in the present paper are in line with this hypothesis, since luminal tumors (ER+) carrying
AR/ER ratio ≥ 2 had higher cell proliferation gene expression (Figures 1A and 2). Besides, our results
support recent reports indicating that BC cases with AR/ER ratio ≥ 2 have both shorter disease-free
interval (DFI) and overall survival (OS) [11,12]. The differences in proliferation observed between
the two groups are not dependent on variable ER expression levels [42,43], because cases divided
by ER% positivity alone did not show significant differences in the cellular proliferation signature
(Figure 1B). Of note, differences were not observed in the expression of the main IHC proliferation
marker—Ki67 among groups. In general, there was a clear positive correlation among methodological
approaches used to assess expression of this marker, however specifically in the AR/ER ≥ 2 group,
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the correlation was not kept (Figures S3 and S4). This suggests that single Ki67-IHC evaluation is not
sensitive enough to identify increased proliferation rates observed in this BC subset. The above can
probably be explained due to a particular biological behavior of this type of tumor and by the intrinsic
low sensitivity of a single IHC marker compared to a multigene panel evaluated by highly sensitive
qPCR assays.
Several studies suggest that high AR expression may contribute to cell proliferation and be
detrimental in luminal BCs. A recent report proved that accelerated degradation of AR promoted
growth arrest and apoptosis, not only in ER-, but also in MCF7 (Luminal) cells, and these effects
were inverted with reintroduction or overexpression of AR [34]. Additional studies showed that
the AR-inhibitor, enzalutamide, abrogate both the androgen and estrogen-induced proliferation of
MCF-7 cells, in vitro, and in MCF-7 xenograft models, in vivo, by inhibiting receptors translocation [11].
Moreover, De Amicis et al. [44], demonstrated that Tamoxifen-resistant tumors express higher levels of
AR with lower levels of ER. The same study also indicated that Tamoxifen stimulates proliferation
and xenograft growth of AR-overexpressing MCF-7 cells. These data are in agreement with results
obtained from clinical specimens in which AR/ER ≥ 2 was associated with increased risk of tamoxifen
resistance [11]. Finally, emerging evidence in ER+ BC cell lines suggest that high AR expression may
also facilitate cell migration because induce CXCL12-CXCR4 expression [45] and downregulation of
E-cadherin [46], both events leading to epithelial-to-mesenchymal transition (EMT) and metastasis.
Altogether, these results suggest the effect of AR as a tumor promoting factor in ER+ BC cells.
Further, to confirm differences in proliferation, bioinformatics analyses on validation cohorts
enabled to determine the molecular subtypes observed in each AR/ER ratio group. Most of the cases
with AR/ER ratio ≥ 2 were assigned to luminal categories (66.7%), however 47.1% of them were
classified as luminal B tumors (Figure 3), characterized by worse prognosis and perceived as a distinct
entity compared with Luminal A subtype [47]. In addition, our analyses showed that almost 30% of
cases with AR/ER ratio ≥ 2 were classified as HER2-enriched subtype, which suggest AR and HER2
signaling pathways may collaborate to regulate HER2-enriched tumors [32]. However, it is important
to note that differences in proliferation are not only explained by higher HER2 expression/amplification,
since ER+/HER2- cases with AR/ER ratio ≥ 2 also had higher levels of cellular proliferation markers
(Figure 1C). Although functional crosstalks between AR and HER2 have been described mainly in ER-
cells [48], genomic AREs could cause rapid initiation of cytoplasmic signaling cascades (non-genomic
mechanisms), like the ErbB (HER family) and MAPK signaling in ER+ cells too [49]. Since these
pathways has been associated not only with higher proliferation but also with TAM resistance [50],
the evaluation of AR expression in breast tumors, could help to detect a subset of cases possibly
AR-driven, as suggested by the AR-ness signature on cases with AR/ER ratio≥ 2 (Figure 4), which would
benefit from anti-AR tailored therapies.
The main limitation of this work was the low number of samples, however analysis on the
validation cohort with big number of patients from public databases allowed us to consolidate
our data. Although age-related differences were not found in the cases studied (Italian cohort),
significant variations, in this regard, were observed in the validation cohort. This contrasting data
could be explained, not only, by differences in the number of cases analyzed, but also by differences
in the racial/ethnic background composing each of the study populations. Hence, further studies
including larger cohorts of patients are needed to figure out these issues and to verify our results.
5. Conclusions
In line with previous reports which indicate that BC cases with AR/ER ratio ≥ 2 are characterized
to have worse survival, we found that tumors in this group also have higher expression levels of cellular
proliferation genes. This was further validated by molecular subtyping using PAM50, since cases with
AR/ER ratio ≥ 2 were mainly assigned to luminal B and HER2-enriched subtypes, characterized for
higher proliferation and poorer prognoses. Although it has been demonstrated that AR expression
is variable across subtypes and that its expression cannot be used as an independent biomarker,
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our analysis shows that joint routine evaluation of AR and ER expression, should be considered to
identify a unique subset of tumors which potentially would benefit from combination of classical and
anti-AR based therapies.
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